Capecitabine
Metastasis From Malignant Tumor Of Colon
Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Jun Huang
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07381309CT.gov Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM | — | Not Yet Recruiting | — | — | — |
NCT06555133CT.gov Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC | — | Recruiting | — | — | — |
NCT06788171CT.gov PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM | — | Not Yet Recruiting | — | — | — |
NCT05861505CT.gov COLLISION RELAPSE Trial | — | Recruiting | — | — | — |
NCT04701281CT.gov Study of Intra-Arterial Oxaliplatin Plus Capecitabine to Treat Liver Metastases From Colorectal Cancer | — | Terminated | — | — | — |
NCT04108481CT.gov Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer | — | Terminated | — | — | — |
NCT04416854CT.gov The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer | — | Unknown | — | — | — |
NCT04202978CT.gov Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer | — | Unknown | — | — | — |
NCT02291744CT.gov A Phase Ⅱ Study of XELOX Chemotherapy With or Without Surgery of Primary Lesion for Colon Cancer Patients | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastasis From Malignant Tumor Of Colon
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Capecitabine (this asset) | Jun Huang | P3 | BB · 68 |
| Oxaliplatin | Fudan University | P4 | BBB |
| Fruquintinib | Peking University | P3 | BBB |
| Dexasone | Fudan University | P3 | BB |
| Irinotecan | Jun Huang | P3 | BB |
| Cetuximab | Shanghai 6th People's Hospital | P3 | BB |
| Floxuridine | Fudan University | P3 | BB |
| Panitumumab | University of Campania Luigi Vanvitelli | P2 | BB |
| ip-001 | Immunophotonics, Inc. | P2/3 | BB |
+42 more in the Metastasis From Malignant Tumor Of Colon cohort
Other indications for Capecitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Carcinoma | — | P4 | BBB · 73 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 72 |
| Colorectal Neoplasm | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Capecitabine in Metastasis From Malignant Tumor Of Colon. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/capecitabine-metastasis-from-malignant-tumor-of-colon
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →